Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults

Med（2022）

引用 11|浏览11

暂无评分

摘要

•Heterologous schedule was well tolerated in a cohort of 810 adults aged 19–80 years•Specific IgG and neutralizing antibody responses were observed after vaccination•Neutralizing GMT versus D614G variant persisted after 7–8 months of vaccination•Serum samples of vaccinees neutralized VOCs Alpha, Beta, Delta, and Omicron

查看译文

关键词

conjugate vaccine,heterologous schedule,COVID-19,recombinant RBD,phase IIb clinical trial

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要